Novo Nordisk (NVO)
(Delayed Data from NYSE)
$127.51 USD
-7.37 (-5.46%)
Updated Sep 20, 2024 04:02 PM ET
After-Market: $127.94 +0.43 (0.34%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NVO 127.51 -7.37(-5.46%)
Will NVO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NVO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NVO
NVO Stock Loses Around $29B in 3 Months: Buy the Dip or Steer Clear?
NVO Gets Positive CHMP Opinion for Wegovy's Label Update in EU
NVO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sanofi Stock Up Almost 23% in 3 Months: Buy, Sell or Hold?
Pfizer Stock Rises 7.3% in 3 Months: Should You Invest Now?
Novo Nordisk (NVO) Gains As Market Dips: What You Should Know
Other News for NVO
Eli Lilly: Sticking With A $1000 Target Ahead Of Q3 Earnings, New Trading Range
UnitedHealth, Cigna, CVS PBMs targeted by FTC over inflated insulin prices
Novo Nordisk down 6% on data for oral weight loss drug monlunabant
Novo Nordisk down 6% on data for oral weight loss drug monlunabant
Novo Nordisk down 6% on data for oral weight loss drug onlunabant